$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
Monteverde & Associates PC announced an investigation into Supernus Pharmaceuticals regarding its proposed sale to Indivior Pharmaceuticals. The transaction terms specify that Supernus shareholders are expected to receive 1.5401 common shares of Indivior for each share of Supernus.
Key figures
- Exchange ratio
- 1.5401
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.